Therefore, the PD-1/PD-L1 axis represents an important immune checkpoint, and its targeting with monoclonal antibodies has been proven to be an effective immunotherapeutic strategy, demonstrating durable clinical responses and improved survival in several tumor types [3]. This evidence concerns the gene CD274 and neoplasm.